|

Interview With David Champion

ByPsychedelic Spotlight

Similar Posts

  • MindMed To Deliver Psychedelics Directly To The Brain? (MMED / MNMD)

    Listen, Videos

    MindMed (MMED :NEO), (MNMD:NASDAQ), (MMQ: FRA) is testing the delivery of psychedelics compounds directly to the brain!?

    What is the best way to take a psychedelic medicine? Is it in a format of a pill, a film strip which dissolves under the tongue, or maybe an injection? These are the standard delivery methods we’re all familiar with.
    But what if we could deliver a psychedelic medicine directly to the brain, and thus negate any potentially negative side effects of the drug interacting with the body?
    Answering this question is the purpose of a new MindMed partnership.

    In this episode, we’ll explore MindMed’s new partnership with Nextage Therapeutics, their Brain Targeting Liposome System (BTLS), and it’s applications.

    Enjoy the episode!

    Link:
    https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Website: https://thepsychedelicinvestor.com/
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MNMD #MindmedNews

  • MindMed ‘s Plan to END the Opioid Epidemic (How MMED / MMEDF Could Make Billions)

    Listen, Videos

    It is an unfortunate fact that the world is dealing with a second hidden epidemic: The Opioid Crisis. Luckily, MindMed ( MMED/ MMEDF ) has a solution: 18-MC. This Psychedelic Medicines company, which may soon be uplisted to the Nasdaq, is testing it’s ibogaine derivative to heal those effected by opioid addiction, whether from fentanyl or doctors’ prescriptions. We may have a light at the end of the tunnel, and the Opioid Epidemic may be defeated. This makes MindMed one of the best stocks for 2021. How much could this be worth? Tune in to find out!

    Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    Resources

    https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm

    https://www.ncbi.nlm.nih.gov/books/NBK541390/#:~:text=Morethan2millionpeople,diseasestraumaandsuicide.

    https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html#:~:text=In2018anestimated10.3,and808000peopleusedheroin.&text=Appropriateprescribingofopioidsis,andsafetyofMedicarebeneficiaries.

    https://www.ccsa.ca/opioids#:~:text=Canadaisinthemidst,publichealthandsafetyconcern.

    https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17477

    https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en

    https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction

    https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery

    https://preprod.drugfree.org/article/relapse-overdose/

    https://mindmed.co/psychedelic-inspired/#scroll_section-1

    https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

    https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

    https://s3.ca-central-1.amazonaws.com/ibosafe-pdf-resources/Ibogaine/Treating+drug+dependence+with+the+aid+of+ibogaine_a+retrospective+study.pdf

    https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

    https://thethirdwave.co/psychedelics/ibogaine/

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382526/#:~:text=Theantiaddictiondrugibogainecertainlyaffectstheheartand,ibogaine’spotentiallylifethreateningcardiotoxicity.

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf

    https://www.ibogainealliance.org/18-mc/

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf

    #MindMed #MMED #MMEDF #MindMedNews #OpioidEpidemic #OpioidCrisis #MindMedStock #18MC #18-MC #PsychedelicStocks

  • BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study

    Listen, Videos

    HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).

    This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.

    In this episode we will discuss:
    – The details of this trial and why it is so important;
    – The big update that we have for you;
    – When we can expect results;
    – Where the field goes from here in the near future.

    Timestamps:

    0:00 – Intro
    1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
    6:57 – The major Update on CMPS’ Clinical Trial
    8:07 – Anticipated results date & what these results will mean for the psychedelic industry

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #CMPS #PsychedelicTherapy